Magazine Article | October 4, 2018

Apellis Advances On Autoimmunity

Source: Life Science Leader

By Wayne Koberstein, Executive Editor, Life Science Leader magazine
Follow Me On Twitter @WayneKoberstein

Deliberate invention, aimed at starting a biopharma business, can be a valid, creative, and sometimes rewarding enterprise. Many or perhaps most of the companies in this space begin as a scientific concept looking for a medical application. But examples of the opposite model — gathering appropriate expertise around the table to identify and select a scientific target for a new business — could be rare. In the case of Apellis, the way less traveled began with a relatively safe sendoff. The company was born from the winning entry of the 2001 Harvard Business School Business Plan Competition, but then only as a concept, called Potentia Pharmaceuticals. Although the plan envisioned therapeutic applications involving nanobiotechnology to support the then popular approach of high-throughput screening (HTS), the underlying science and technology were then nonexistent.

VIEW THE MAGAZINE ARTICLE!
Signing up provides unlimited access to:
Signing up provides unlimited access to:
  • Trend and Leadership Articles
  • Case Studies
  • Extensive Product Database
  • Premium Content
HELLO. PLEASE LOG IN. X

Not yet a member of Life Science Leader? Register today.

ACCOUNT SIGN UP X
Please fill in your account details
Login Information
I'm interested in newsletter subscriptions.
ACCOUNT SIGN UP

Subscriptions

Sign up for the newsletter that brings you the industry's latest news, technologies, trends and products.

You might also want to: